Anebulo Pharmaceuticals
ANEB
ANEB was delisted on the 27th of February, 2026.
21 hedge funds and large institutions have $55.5M invested in Anebulo Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 6 closing their positions.
71% more capital invested
Capital invested by funds: $32.5M → $55.5M (+$23M)
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
17% more funds holding
Funds holding: 18 → 21 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.91% less ownership
Funds ownership: 54.99% → 54.08% (-0.91%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$213K |
| 2 |
Renaissance Technologies
New York
|
+$67.1K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$57.4K |
| 4 |
RC
Rangeley Capital
New Canaan,
Connecticut
|
+$47.1K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$45.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LA
LVW Advisors
Pittsford,
New York
|
-$503K |
| 2 |
Millennium Management
New York
|
-$221K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$74.4K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$36K |
| 5 |
Goldman Sachs
New York
|
-$16.7K |
ANEB Hedge Fund Activity: Q3 2025 in Review
21 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Anebulo Pharmaceuticals (ANEB) for Q3 2025, worth a combined $55.5M — up 71% from $32.5M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ANEB positions and 6 closed out — a net gain of 3 holders — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $213K. The largest seller was LVW Advisors, exiting entirely with an estimated $503K sold.
- 21 institutional investors held Anebulo Pharmaceuticals (ANEB) as of Q3 2025, up from 18 in Q2 2025.
- Funds reported $55.5M of Anebulo Pharmaceuticals stock for Q3 2025, up 71% quarter-over-quarter.
- 9 funds opened new Anebulo Pharmaceuticals positions in Q3 2025 and 6 closed out, a net change of +3 holders.
- The largest Anebulo Pharmaceuticals buyer in Q3 2025 was Vanguard Group, an estimated $213K added.
- The largest Anebulo Pharmaceuticals seller in Q3 2025 was LVW Advisors, an estimated $503K sold.
Based on aggregated 13F filings for Q3 2025.